PHAXIAM takes stock of its activities and publishes its results for the first half of 2023 – 09/21/2023 at 10:05 p.m.

Creation of PHAXIAM Therapeutics with effect from June 23, 2023, in order to form a world leader in phage therapy targeting high value-added indications Development of an ambitious and value-creating clinical and regulatory strategy in the field of severe and resistant bacterial infectionso Launch of a first global pivotal phase 2b/3 study in osteoarticular prosthesis…

Read More

Theradiag publishes its results for the first half of 2023 and shows significantly improved profitability – 09/18/2023 at 07:30

• Achievement of a strong operating margin of 12.5%, reflecting the significant improvement in industrial margins in Theradiag’s two businesses and the cessation of activities in the United States • Cash flow controlled at €5.7 million as of June 30, 2023 and increasing in Q2 2023 Croissy-Beaubourg, September 18, 2023, 7:30 a.m. CEST – THERADIAG…

Read More

SpineGuard publishes its results for the first half of 2023 – 09/12/2023 at 6:15 p.m.

PARIS (France) and BOULDER (Colorado, United States), September 12, 2023 – 6:15 p.m. (CEST) – SpineGuard (FR0011464452–ALSGD), innovative company deploying its digital real-time surgical guidance (DSG®) technology to secure and simplify the placement of bone implants, announces its results for the first half of the financial year, ending June 30, 2023, approved by the Board…

Read More

Scholz receives fictitious rebuff: PiS party publishes anti-German election ad

Scholz collects fictitious rebuff PiS party publishes anti-German election advert September 11, 2023, 4:07 p.m Listen to article This audio version was artificially generated. More info | Send feedback Parliamentary elections will take place in Poland in October. In the election campaign, the national conservative ruling party PiS continues to rely on anti-German tones. In…

Read More

Valneva: Valneva lab publishes positive data in adolescents for its anti-chikungunya vaccine

(BFM Bourse) – The company communicated on Monday data on the safety of this vaccine while those on immunogenicity will be published in November. Valneva is taking a step towards the potential extension of its chikungunya vaccine to adolescents. The specialist in vaccines against infectious diseases had already published positive results for a phase 3…

Read More